GleamWall
中文EN

NEUP Neuphoria Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1191070 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY47.5%
TTM EPS YoY127.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-27.6%
ROA-18.3%
ROIC (approx.)-568.0%
Asset turnover—

Leverage & solvency

Liabilities / assets13.4%
Debt / equity0.00x
Current ratio18.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.95x
Accruals ratio17.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312025Q22025-12-312025Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue—————-$13,267$15.00M$662,715
R&D expense———$697,723$3.79M$3.75M$1.62M$1.74M
SG&A expense$2.10M$1.76M$1.69M$2.13M$1.87M$2.07M$1.41M$2.63M
Operating income-$2.10M-$5.53M-$1.21M-$4.06M-$5.65M-$5.84M$11.98M-$3.70M
Pretax income-$1.46M-$4.94M-$539,856$1.83M-$9.94M-$9.15M$11.18M-$1.93M
Income tax-$34,793-$34,793-$34,793-$34,794-$34,793-$266,602-$81,186$11,609
Net income-$1.43M-$4.90M-$505,063$1.86M-$9.91M-$8.88M$11.26M-$1.94M
EBITDA-$1.93M-$5.36M-$1.05M-$3.90M-$5.49M-$5.67M$12.14M-$3.54M
EPS (basic)-0.26—-0.090.41-4.41—6.55-1.23
EPS (diluted)-0.26—-0.09-0.77-4.41—6.55-1.79
Weighted avg. shares (diluted)5.41M—5.41M4.54M2.25M—1.72M1.58M
Balance sheet
Cash & equivalents$18.74M$19.87M$19.44M$22.17M$13.65M$14.29M$17.04M$4.34M
Receivables$700,219$813,431$1.61M$1.11M$1,758$11,948$24,592$35,561
Current assets$19.60M$21.07M$21.66M$23.39M$13.95M$15.04M$17.09M$4.40M
PP&E, net————$2,573$2,771$1,623$1,683
Goodwill$3.53M$3.50M$8.84M$8.74M$8.67M$8.64M$8.45M$8.41M
Intangibles$3.98M$4.14M$4.31M$4.47M$4.64M$4.80M$4.97M$5.14M
Total assets$27.11M$28.71M$34.81M$36.60M$27.34M$28.59M$30.71M$18.17M
Current liabilities$1.09M$756,581$1.51M$2.59M$5.12M$4.22M$1.55M$2.13M
Total liabilities$3.63M$4.11M$5.39M$6.90M$14.83M$9.59M$4.72M$4.42M
Shareholders' equity$23.47M$24.60M$29.42M$29.70M$12.51M$19.00M$26.00M$13.75M
Shares outstanding5.41M5.41M5.38M5.38M2.36M1.98M1.85M1.63M
Cash flow statement
Operating cash flow-$1.13M$1.21M-$3.34M-$6.44M-$3.79M-$3.59M$11.45M-$3.36M
Financing cash flow—$0$0$14.66M$3.25M$704,675$1.16M-$111,562
Depreciation & amortization$165,683$165,679$165,695$165,789$165,792$165,625$165,431$166,121
Stock-based compensation$74,718$76,336$70,286$93,701$111,277$98,267$19,685$19,084

Free plan shows the latest 8 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.